APA (7th ed.) Citation

M, S., L, S., A, B., T, L., H, X., L, P., . . . SE, B. (2026). Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 84, 101312. https://doi.org/10.1016/j.drup.2025.101312

Chicago Style (17th ed.) Citation

M, Safari, et al. "Combined HDAC and EIF4A Inhibition: A Novel Epigenetic Therapy for Pancreatic Ductal Adenocarcinoma." Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 84 (2026): 101312. https://doi.org/10.1016/j.drup.2025.101312.

MLA (9th ed.) Citation

M, Safari, et al. "Combined HDAC and EIF4A Inhibition: A Novel Epigenetic Therapy for Pancreatic Ductal Adenocarcinoma." Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, vol. 84, 2026, p. 101312, https://doi.org/10.1016/j.drup.2025.101312.